Targeting Inflammation and Iron Deficiency in Heart Failure: A Focus on Older Adults DOI Creative Commons
Daniela Maidana, Andrea Arroyo-Álvarez, Guillermo Barreres-Martín

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 462 - 462

Published: Feb. 13, 2025

Background/Objectives: Heart failure (HF) is a leading cause of morbidity and mortality worldwide, with higher prevalence among older adults. Iron deficiency (ID), affecting up to 50% HF patients, closely linked chronic inflammation, exacerbating outcomes. This review aims explore the interplay between ID, HF, focusing on identify therapeutic gaps emerging treatment strategies. Methods: A comprehensive literature was conducted, emphasizing pathophysiological mechanisms inflammation ID in challenges current diagnostic criteria, limitations available treatments. Emerging pharmacological approaches were analyzed. Results: Chronic particularly adults, promotes functional through elevated hepcidin levels, impairing iron availability worsening anemia. Current relying heavily ferritin, often misclassify due inflammation. Intravenous (IV) therapy shows clinical benefits patients <50% left ventricular ejection fraction (LVEF), but evidence limited heart preserved (HFpEF). therapies, such as Sodium-Glucose Cotransporter-2 inhibitors (SGLT2is) prolyl hydroxylase like Roxadustat, offer promising avenues improve metabolism Conclusions: significantly impact progression, inolder Refining criteria exploring innovative therapies are critical addressing these challenges. Future research should prioritize personalized targeting especially underrepresented populations, HFpEF elderly patients.

Language: Английский

Targeting Inflammation and Iron Deficiency in Heart Failure: A Focus on Older Adults DOI Creative Commons
Daniela Maidana, Andrea Arroyo-Álvarez, Guillermo Barreres-Martín

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 462 - 462

Published: Feb. 13, 2025

Background/Objectives: Heart failure (HF) is a leading cause of morbidity and mortality worldwide, with higher prevalence among older adults. Iron deficiency (ID), affecting up to 50% HF patients, closely linked chronic inflammation, exacerbating outcomes. This review aims explore the interplay between ID, HF, focusing on identify therapeutic gaps emerging treatment strategies. Methods: A comprehensive literature was conducted, emphasizing pathophysiological mechanisms inflammation ID in challenges current diagnostic criteria, limitations available treatments. Emerging pharmacological approaches were analyzed. Results: Chronic particularly adults, promotes functional through elevated hepcidin levels, impairing iron availability worsening anemia. Current relying heavily ferritin, often misclassify due inflammation. Intravenous (IV) therapy shows clinical benefits patients <50% left ventricular ejection fraction (LVEF), but evidence limited heart preserved (HFpEF). therapies, such as Sodium-Glucose Cotransporter-2 inhibitors (SGLT2is) prolyl hydroxylase like Roxadustat, offer promising avenues improve metabolism Conclusions: significantly impact progression, inolder Refining criteria exploring innovative therapies are critical addressing these challenges. Future research should prioritize personalized targeting especially underrepresented populations, HFpEF elderly patients.

Language: Английский

Citations

0